NCT03757325 is a Phase 1 clinical trial of DNL747 in Alzheimer Disease, sponsored by Denali Therapeutics Inc..

Who is sponsoring NCT03757325?

NCT03757325 is sponsored by Denali Therapeutics Inc..

What drugs are being tested in NCT03757325?

Interventions in NCT03757325: DNL747, Placebo.

What condition does NCT03757325 study?

NCT03757325 studies Alzheimer Disease.

Is NCT03757325 still recruiting?

NCT03757325 is currently completed. Last updated 26 February 2020.

Last reviewed 2020-02-26 · How we verify

NCT03757325

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

Completed Phase 1 Last updated 26 February 2020

What this trial tests

Phase 1 trial testing DNL747 in Alzheimer Disease in 16 participants. Completed in 5 December 2019.

Timeline

13 February 2019

Primary endpoint
5 December 2019

5 December 2019

Quick facts

Lead sponsor	Denali Therapeutics Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	16
Start date	13 February 2019
Primary completion	5 December 2019
Estimated completion	5 December 2019
Sites	5 locations across Netherlands, United States

Drugs / interventions tested

DNL747 — full drug profile →
Placebo

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Denali Therapeutics Inc. — full company profile →

Who can join

Adults 55 to 85, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Alzheimer's disease when administered for 29 days in a cross-over design

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular mechanisms of cell death in neurological diseases.
Moujalled D, Strasser A, Liddell JR. · · 2021 · cited 513× · PMID 34099897 · DOI 10.1038/s41418-021-00814-y
Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.
Mifflin L, Ofengeim D, Yuan J. · · 2020 · cited 350× · PMID 32669658 · DOI 10.1038/s41573-020-0071-y
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease.
Nguyen TT, Wei S, Nguyen TH, Jo Y, et al · · 2023 · cited 221× · PMID 37612409 · DOI 10.1038/s12276-023-01046-5
Molecular Insights into the Mechanism of Necroptosis: The Necrosome As a Potential Therapeutic Target.
Chen J, Kos R, Garssen J, Redegeld F. · · 2019 · cited 135× · PMID 31766571 · DOI 10.3390/cells8121486
Cell Death and Neurodegeneration.
Andreone BJ, Larhammar M, Lewcock JW. · · 2020 · cited 85× · PMID 31451511 · DOI 10.1101/cshperspect.a036434
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers MFJM, Heuberger JAAC, Groeneveld GJ, Oude Nijhuis J, et al · · 2022 · cited 70× · PMID 35649245 · DOI 10.1111/cts.13317
RIPK protein kinase family: Atypical lives of typical kinases.
Cuny GD, Degterev A. · · 2021 · cited 68× · PMID 32732131 · DOI 10.1016/j.semcdb.2020.06.014

Verify or expand the search:

Other trials of DNL747

Trials testing the same drug.

NCT03757351 — Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis · Phase 1 · terminated

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Denali Therapeutics Inc. trials

Trials by the same sponsor.

NCT06602193 — Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) · Phase 2 · recruiting
NCT06281158 — A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in · Phase 1 · completed
NCT05450549 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants · Phase 1 · completed
NCT05006352 — A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Later · Phase 1 · completed
NCT04581772 — A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03757325 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Denali Therapeutics Inc.
Last refreshed: 26 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03757325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing